Detalles de la búsqueda
1.
Safety and tolerability of dexmecamylamine (TC-5214) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to antidepressant therapy: results of a long-term study.
J Clin Psychopharmacol;
35(1): 77-81, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25514064
2.
Rare deletions at 16p13.11 predispose to a diverse spectrum of sporadic epilepsy syndromes.
Am J Hum Genet;
86(5): 707-18, 2010 May 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-20398883
3.
Common genetic variation and susceptibility to partial epilepsies: a genome-wide association study.
Brain;
133(Pt 7): 2136-47, 2010 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-20522523
4.
An assessment of the Irish population for large-scale genetic mapping studies involving epilepsy and other complex diseases.
Eur J Hum Genet;
16(2): 176-83, 2008 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-17971835
5.
Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease.
Arch Neurol;
65(1): 45-53, 2008 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-17998437
6.
Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease.
J Alzheimers Dis;
14(3): 301-11, 2008 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-18599956
7.
Partnership between academia and industry for drug discovery in Alzheimer's disease.
Alzheimers Dement;
4(2): 80-8, 2008 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-18631952
8.
Multicentre search for genetic susceptibility loci in sporadic epilepsy syndrome and seizure types: a case-control study.
Lancet Neurol;
6(11): 970-80, 2007 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-17913586
9.
Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia.
Schizophr Bull;
42(2): 335-43, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26071208
10.
Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy.
World J Biol Psychiatry;
16(7): 483-501, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25602163
11.
AZD3480, a novel nicotinic receptor agonist, for the treatment of attention-deficit/hyperactivity disorder in adults.
Biol Psychiatry;
75(3): 207-14, 2014 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23856296
12.
Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressant.
Eur Neuropsychopharmacol;
24(4): 564-74, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24507016
13.
A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia.
Neuropsychopharmacology;
38(6): 968-75, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23303043
14.
The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone.
Biomarkers;
13(6): 618-36, 2008 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-18830857
15.
Pharmacogenetics to predict drug-related adverse events.
Toxicol Pathol;
32 Suppl 1: 9-12, 2004.
Artículo
en Inglés
| MEDLINE | ID: mdl-15209398
Resultados
1 -
15
de 15
1
Próxima >
>>